Therapie der Benzodiazepinabhängigkeit

Langzeitverordnungen von Benzodiazepinen entfallen vor allem auf ältere und weibliche Patienten. Entzugsbehandlungen sollten schrittweise über einen mehrwöchigen Zeitraum erfolgen. Begleitende Schlaf- und depressive Störungen im Benzodiazepinentzug kann man am ehesten mit sedierenden Antidepressiva behandeln. Die spärliche Studienlage deutet auf eine gewisse Effizienz von Psychoedukation, motivationalen Strategien und kognitiver Verhaltenstherapie.

Long-term prescriptions of benzodiazepines are made mainly to elderly and female patients. Withdrawal treatments should be carried out gradually over a period of several weeks. Sleep and depressive disorders during benzodiazepine withdrawal can best be treated with sedating antidepressants. The few studies on this subject suggest psychoeducation, motivational strategies and cognitive behavioural therapy as having some efficacy.

Schlüsselwörter

Benzodiazepine - Abhängigkeit - Entzug - Therapie

Keywords

Benzodiazepine - dependence - withdrawal - treatment

• Literatur

• 1 Soyka M. Medikamentenabhängigkeit. Stuttgart: Schattauer; 2015
• 2 Soyka M, Queri S, Kufner H. et al. [Where are the 1.9 million patients dependent on legal drugs hiding?]. Nervenarzt 2005; 76: 72-77
• 3 Janhsen K, Roser P, Hoffmann K. The problems of long-term treatment with benzodiazepines and related substances. Dtsch Arztebl Int 2015; 112: 1-7
• 4 Petitjean S, Ladewig D, Meier CR. et al. Benzodiazepine prescribing to the Swiss adult population: results from a national survey of community pharmacies. Int Clin Psychopharmacol 2007; 22: 292-298
• 5 Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiatry 2015; 72: 136-142
• 6 Buth S, Holzbach R, Rosenkranz M. et al. Der Gebrauch von Medikamenten mit Abhängigkeitspotenzial in Deutschland. Eine prospektive Analyse kassenärztlicher Verschreibungen der Jahre 2006 bis 2010. Bundesgesundheitsbl 2017; 60: 865-872
• 7 Pabst A, Kraus L, Gomes de Matos E. et al. Substanzkonsum und substanzbezogene Störungen in Deutschland im Jahr 2012. Sucht 2013; 59: 321-331
• 8 Huang B, Dawson DA, Stinson FS. et al. Prevalence, correlates, and comorbidity of nonmedical prescription drug use and drug use disorders in the United States: Results of the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2006; 67: 1062-1073
• 9 Kurko TA, Saastamoinen LK, Tahkapaa S. et al. Long-term use of benzodiazepines: Definitions, prevalence, and usage patterns – a systematic review of register-based studies. Eur Psychiatry 2015; 30: 1037-1047
• 10 Neutel CI. The epidemiology of long-term benzodiazepine use. Int Rev Psychiatry 2005; 17: 189-197
• 11 Okumura Y, Shimizu S, Matsumoto T. Prevalence, prescribed quantities, and trajectory of multiple prescriber episodes for benzodiazepines: A 2-year cohort study. Drug Alcohol Depend 2016; 158: 118-125
• 12 Davies J, Rae TC, Montagu L. Long-term benzodiazepine and Zdrugs use in the UK: a survey of general practice. Br J Gen Pract 2017; 67: e609-e613
• 13 Amato L, Minozzi S, Vecchi S. et al. Benzodiazepines for alcohol withdrawal. Cochrane Database Syst Rev 2010 (03) : CD005063
• 14 Baldwin DS, Aitchison K, Bateson A. et al. Benzodiazepines: risks and benefits. A reconsideration. J Psychopharmacol 2013; 27: 967-971
• 15 Benkert O, Hippius H. Kompendium der Psychiatrischen Pharmakotherapie. 9.. Aufl. Berlin, Heidelberg: Springer; 2013
• 16 Buffett-Jerrott SE, Stewart SH. Cognitive and sedative effects of benzodiazepine use. Curr Pharm Des 2002; 8: 45-58
• 17 Mura T, Proust-Lima C, Akbaraly T. et al. Chronic use of benzodiazepines and latent cognitive decline in the elderly: results from the Three-city study. Eur Neuropsychopharmacol 2013; 23: 212-223
• 18 Pariente A, de Gage SB, Moore N. et al. The benzodiazepine-dementia disorders link: Current state of knowledge. CNS Drugs 2016; 30: 1-7
• 19 Jones JD, Mogali S, Comer SD. Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend 2012; 125: 8-18
• 20 Lintzeris N, Nielsen S. Benzodiazepines, methadone, and buprenorphine: interactions and clinical management. Am J Addict 2010; 19: 59-72
• 21 Bachhuber MA, Hennessy S, Cunningham CO. et al. Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996-2013. Am J Public Health 2016; 106: 686-688
• 22 Gustavsen I, Bramness JG, Skurtveit S. et al. Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam. Sleep Med 2008; 9: 818-822
• 23 Smink BE, Egberts AC, Lusthof KJ. et al. The relationship between benzodiazepine use and traffic accidents: A systematic literature review. CNS Drugs 2010; 24: 639-653
• 24 Hollister LE, Motzenbecker FP, Degan RO. Withdrawal reactions from chlordiazepoxide (“Librium”). Psychopharmacologia 1961; 2: 63-68
• 25 Tan KR, Brown M, Labouebe G. et al. Neural bases for addictive properties of benzodiazepines. Nature 2010; 463: 769-774
• 26 Lüscher C, Ungless MA. The mechanistic classification of addictive drugs. PLoS Med 2006; 3: e437
• 27 World Health Organization. The ICD‑10 Classification of Mental and Behavioral Disorders. Clinical Descriptions and Disgnostic Guidelines. Geneva: World Health Organization; 1992
• 28 Ashton H. Benzodiazepine Abuse. In: Caan W, de Belleroche J. , eds. Drink, Drugs, and Dependence from Science to clinical Practice. London, New York: Routledge; 2002: 197-212
• 29 Lader M, Kyriacou A. Withdrawing benzodiazepines in patients with anxiety disorders. Curr Psychiatry Rep 2016; 18: 8
• 30 Lader M, Tylee A, Donoghue J. Withdrawing benzodiazepines in primary care. CNS Drugs 2009; 23: 19-34
• 31 Lader M. Benzodiazepines revisited – will we ever learn? Addiction 2011; 106: 2086-2109
• 32 Darker CD, Sweeney BP, Barry JM. et al. Psychosocial interventions for benzodiazepine harmful use, abuse or dependence. Cochrane Database Syst Rev 2015 (05) : CD009652
• 33 Denis C, Fatseas M, Lavie E. et al. Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings. Cochrane Database Syst Rev 2006 (03) : CD005194
• 34 Mugunthan K, McGuire T, Glasziou P. Minimal interventions to decrease long-term use of benzodiazepines in primary care: a systematic review and meta-analysis. Br J Gen Pract 2011; 61: e573-e578
• 35 Parr JM, Kavanagh DJ, Cahill L. et al. Effectiveness of current treatment approaches for benzodiazepine discontinuation: a meta-analysis. Addiction 2009; 104: 13-24
• 36 Sirdifield C, Chipchase SY, Owen S. et al. A systematic review and meta-synthesis of patientsʼ experiences and perceptions of seeking and using benzodiazepines and Z-drugs: Towards safer prescribing. Patient 2017; 10: 1-15
• 37 Lingford-Hughes AR, Welch S, Peters L. et al. BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. J Psychopharmacol 2012; 26: 899-952
• 38 Soyka M, Steinberg R, Vollmer M. [Withdrawal phenomena in stepwise withdrawal of benzodiazepines]. Nervenarzt 1988; 59: 744-748
• 39 Soyka M, Batra A. Benzodiazepin-Abhängigkeit. In: Vorderholzer U. , Hohagen F. , Hrsg. Therapie psychischer Erkrankungen State of the Art. München: Urban und Fischer; 2014: 55
• 40 Soyka M. Treatment of benzodiazepine dependence. N Engl J Med 2017; 376: 1147-1157
• 41 Nielsen S, Dietze P, Lee N. et al. Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment. Addiction 2007; 102: 616-622
• 42 Baandrup L, Fagerlund B, Jennum P. et al. Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia: a randomized clinical trial – the SMART trial protocol. BMC Psychiatry 2011; 11: 160
• 43 Baandrup L, Glenthoj BY, Jennum PJ. Objective and subjective sleep quality: Melatonin versus placebo add-on treatment in patients with schizophrenia or bipolar disorder withdrawing from long-term benzodiazepine use. Psychiatry Res 2016; 240: 163-169
• 44 Mariani JJ, Malcolm RJ, Mamczur AK. et al. Pilot trial of gabapentin for the treatment of benzodiazepine abuse or dependence in methadone maintenance patients. Am J Drug Alcohol Abuse 2016; 42: 333-340
• 45 Berglund M, Thelander S, Jonsson E. Treating alcohol and drug abuse: An evidence based review. Weinheim: Wiley-VCH Verlag; 2003
• 46 Dutra L, Stathopoulou G, Basden SL. et al. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry 2008; 165: 179-187
• 47 Ten Wolde GB, Dijkstra A, van Empelen P et al. Long-term effectiveness of computer-generated tailored patient education on benzodiazepines: a randomized controlled trial. Addiction 2008; 103: 662-670
• 48 Oude Voshaar RC, Gorgels WJ, Mol AJ. et al. Long-term outcome of two forms of randomised benzodiazepine discontinuation. Br J Psychiatry 2006; 188: 188-189
• 49 Voshaar RC, Gorgels WJ, Mol AJ. et al. Tapering off long-term benzodiazepine use with or without group cognitive-behavioural therapy: three-condition, randomised controlled trial. Br J Psychiatry 2003; 182: 498-504
• 50 Otto C, Crackau B, Lohrmann I. et al. Brief intervention in general hospital for problematic prescription drug use: 12-month outcome. Drug Alcohol Depend 2009; 105: 221-226
• 51 de Gier NA, Gorgels WJ, Lucassen PL. et al. Discontinuation of long-term benzodiazepine use: 10-year follow-up. Fam Pract 2011; 28: 253-259
• 52 OʼBrien PL, Karnell LH, Gokhale M. et al. Prescribing of benzodiazepines and opioids to individuals with substance use disorders. Drug Alcohol Depend 2017; 178: 223-230
• 53 U.S.  Food & Drug Administration. FDA Drug Safety Communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. U.S.  Food and Drug Administration; 2016 . Im Internet: http: / /www.fda.gov/Drugs/DrugSafety/ucm518473.htm; Stand: 05.03.2018
• 54 Taburin S, Faccini M, Casari R. et al. Low risk of seizures with slow flumazenil infusion and routine anticonvulsant prophylaxis for high-dose benzodiazepine dependence. J Psychopharmacol 2017; 31: 1369-1373
• 55 Faccini M, Leone R, Opri S. et al. Slow subcutaneous infusion of flumazenil for the treatment of long-term, high-dose benzodiazepine users: a review of 214 cases. J Psychopharmacol 2016; 30: 1047-1053
• 56 Liebrenz M, Boesch L, Stohler R. et al. Agonist substitution – a treatment alternative for high-dose benzodiazepine-dependent patients? Addiction 2010; 105: 1870-1874
• 57 Nissen C, Frase L, Hajak G. et al. [Hypnotics-state of the science]. Nervenarzt 2014; 85: 67-76
• 58 Morin CM, Culbert JP, Schwartz SM. Nonpharmacological interventions for insomnia: a meta-analysis of treatment efficacy. Am J Psychiatry 1994; 151: 1172-1180
• 59 Morgan K, Dixon S, Mathers N. et al. Psychological treatment for insomnia in the regulation of long-term hypnotic drug use. Health Technol Assess 2004; 8 iii-iv, 1-68